Mechanism of Action: Sodium Channel Antagonists
✉ Email this page to a colleague
Drugs with Mechanism of Action: Sodium Channel Antagonists
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sk Life | XCOPRI | cenobamate | TABLET;ORAL | 212839-002 | Mar 10, 2020 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
| Sk Life | XCOPRI | cenobamate | TABLET;ORAL | 212839-005 | Mar 10, 2020 | RX | Yes | No | 7,598,279 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Sk Life | XCOPRI | cenobamate | TABLET;ORAL | 212839-003 | Mar 10, 2020 | RX | Yes | No | 11,654,133 | ⤷ Subscribe | ⤷ Subscribe | ||||
| Sk Life | XCOPRI | cenobamate | TABLET;ORAL | 212839-005 | Mar 10, 2020 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
| Sk Life | XCOPRI | cenobamate | TABLET;ORAL | 212839-003 | Mar 10, 2020 | RX | Yes | No | 7,598,279 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Sk Life | XCOPRI | cenobamate | TABLET;ORAL | 212839-006 | Mar 10, 2020 | RX | Yes | No | 11,654,133 | ⤷ Subscribe | ⤷ Subscribe | ||||
| Sk Life | XCOPRI | cenobamate | TABLET;ORAL | 212839-003 | Mar 10, 2020 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
